Price T Rowe Associates Inc. MD Sells 592,930 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Price T Rowe Associates Inc. MD trimmed its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 94.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,548 shares of the company's stock after selling 592,930 shares during the quarter. Price T Rowe Associates Inc. MD's holdings in Neumora Therapeutics were worth $346,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Neumora Therapeutics during the fourth quarter valued at $61,000. PNC Financial Services Group Inc. bought a new position in shares of Neumora Therapeutics in the fourth quarter worth about $64,000. Quantbot Technologies LP bought a new position in shares of Neumora Therapeutics in the fourth quarter worth about $92,000. PEAK6 LLC bought a new position in shares of Neumora Therapeutics in the fourth quarter worth about $117,000. Finally, EntryPoint Capital LLC bought a new position in shares of Neumora Therapeutics in the fourth quarter worth about $135,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Price Performance

Shares of Neumora Therapeutics stock traded up $0.03 on Friday, reaching $0.70. The company had a trading volume of 1,188,042 shares, compared to its average volume of 1,508,154. Neumora Therapeutics, Inc. has a 1 year low of $0.61 and a 1 year high of $17.19. The firm has a market cap of $113.22 million, a price-to-earnings ratio of -0.37 and a beta of 2.96. The firm's 50-day moving average price is $0.85 and its two-hundred day moving average price is $4.29.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.02). As a group, analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on NMRA shares. Stifel Nicolaus cut Neumora Therapeutics from a "buy" rating to a "hold" rating and cut their target price for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. HC Wainwright dropped their target price on Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Bank of America reiterated an "underperform" rating and issued a $1.00 target price (down previously from $7.00) on shares of Neumora Therapeutics in a report on Wednesday, April 2nd. Royal Bank of Canada reiterated a "sector perform" rating and issued a $4.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Finally, Guggenheim cut Neumora Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Neumora Therapeutics has an average rating of "Hold" and a consensus price target of $9.29.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.